BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering

BERKELEY, Calif., and VANCOUVER, British Columbia, March 20, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it intends to complete a non-brokered private placement of up to 20,000,000 common shares of the Company at a …

BriaCell Welcomes BioPharma Industry Experts to its Board of Directors

BERKELEY, Calif., and VANCOUVER, British Columbia, March 18, 2019 – BriaCell® Therapeutics Corp. (“BriaCell®” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces changes to its Board of Directors. BriaCell® is pleased to welcome the appointment of Dr. Rebecca Taub, M.D., and Mr. Vaughn C. …

BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) — via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with BriaCell Therapeutics Corp. (BCTXF) (BCT.V), a client of NNW and immuno-oncology-focused biotechnology company developing targeted and …

BriaCell Announces C$500,000 Equity Investment by BriaCell Director

BERKELEY, Calif., and VANCOUVER, British Columbia, February 26, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce a non-brokered private placement financing of 5,000,000 common shares of the Company at a price of C$0.10 per common share for …

BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences

· New insights into BriaDX™, BriaCell’s simple patient HLA-type identification test, will be presented at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium held in in San Francisco, California, February 28-March 2, 2019. · Dr. Charles L. Wiseman will be a keynote speaker at Euro Breast Cancer Summit held in Paris, France, March 20-21, 2019. · Scientific findings …

BriaCell Appoints Jamieson Bondarenko to its Board of Directors

BERKELEY, Calif., and VANCOUVER, British Columbia, February 12, 2019 – BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) (“BriaCell” or the “Company”), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces the appointment of Jamieson Bondarenko to the Company’s Board of Directors. Jamieson Bondarenko, CFA, CMT, is an active investor and provides strategic capital …

BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference

· Completed development of a novel frozen formulation of Bria-IMT™ for on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs. · Upcoming attendance at Biotech Showcase in San Francisco, Jan. 7-9, 2019. · Abstract accepted by Keystone Symposia for presentation of advances in Bria-IMT™ and BriaDX™ programs, Jan. 20-24, 2019. …

BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference

· Interim data indicate an excellent safety profile for the combination regimen in advanced breast cancer patients. Initial efficacy data is expected in first quarter of 2019; · Confirmed positive proof-of-concept with Bria-IMT™ Monotherapy demonstrates promising anti-tumor activity with excellent safety and tolerability in advanced breast cancer patients. BERKELEY, Calif., and VANCOUVER, British Columbia, December …

UPDATED – BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

Note: This Press Release contains amendments to the press release previously issued on Nov. 19, 2018 · Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. · Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by …

BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

· Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. · Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) in advanced breast cancer. · Interim safety data of the combination study …